Sales & Marketing News | pharmaphorum

News

November date set for FDA decision on Sanofi's Gaucher drug

The FDA has started a priority review of Sanofi's brain-acting Gaucher disease therapy venglustat, with an action date of 25th November.

News

AbbVie's Immunogen buy delivers rare cancer drug approval

AbbVie's Decnupaz approval will give patients with rare blood cancer BPDCN an alternative to Stemline's Elzonris with a simpler dosing regimen.

News

FDA delays verdict on AZ breast cancer drug

After an advisory committee setback, AstraZeneca has a chance to make the case for its oral SERD camizestrant for breast cancer.

News

Gilead claims first FDA nod for a hepatitis D therapy

At its second attempt, Gilead has won FDA approval for chronic hepatitis D virus drug Hepcludex, four years after it was cleared in the EU.

News

Oral Wegovy backed by CHMP at May meeting

The CHMP recommended eight new medicines and 13 line extensions at its May meeting, including Novo Nordisk's oral weight loss therapy.

News

GBL joins CVC in €10.7bn takeover bid for Recordati

A consortium of investors has made a €10.7bn offer to take Italian pharma Recordati private, but some analysts are sceptical the deal will go through.

November date set for FDA decision on Sanofi's Gaucher drug

AbbVie's Immunogen buy delivers rare cancer drug approval

FDA delays verdict on AZ breast cancer drug

Gilead claims first FDA nod for a hepatitis D therapy

Oral Wegovy backed by CHMP at May meeting

GBL joins CVC in €10.7bn takeover bid for Recordati

Enhertu OK ends 10-year EU gap in frontline breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks